Allianz SE : Back up against a massive resistance level
Entry price | Target | Stop-loss | Potential |
---|
€201.5 |
€191.5 |
€203.9 |
+4.96% |
---|
Allianz shares trade close to a major resistance zone that is situated around 189.4 EUR. This zone should be difficult to break through, which in turn suggests a corrective move ahead.
Summary● The company usually posts poor financials for mid or long term investments.
Strengths● The equity is one of the most attractive in the market with regard to earnings multiple-based valuation.
● The company is one of the best yield companies with high dividend expectations.
● The tendency within the weekly time frame is positive above the technical support level at 177.57 EUR
Weaknesses● Stock prices approach a strong long-term resistance in weekly data at EUR 202.85.
● The stock is close to a major daily resistance at EUR 203.9, which should be gotten rid of so as to gain new appreciation potential.
● With relatively low growth outlooks, the group is not among those with the highest revenue growth potential.
● Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
The content herein constitutes a general investment recommendation, prepared in accordance with provisions aimed at preventing market abuse by Surperformance, the publisher of MarketScreener.com. More specifically, this recommendation is based on factual elements and expresses a sincere, complete, and balanced opinion. It relies on internal or external data, considered reliable as of the date of their release. Nevertheless, this information, and the resulting recommendation, may contain inaccuracies, errors, or omissions, for which Surperformance cannot be held responsible. This recommendation, which in no way constitutes investment advice, may not be suitable for all investor profiles. The reader acknowledges and accepts that any investment in a financial instrument involves risks, for which they assume full responsibility, without recourse against Surperformance. Surperformance commits to disclosing any conflict of interest that may affect the objectivity of its recommendations.